Home » Drug Information
View By:YearCompanyConditionsTherapeutic AreasDrug Names
2013201220112010200920082007200620052004200320022001200019991998199719961995
FDA Approved Drugs
The following database contains a listing of drugs approved by the Food and Drug Administration (FDA) for sale
in the United States. Drug information typically includes the drug name, approval status, indication of use, and
clinical trial results.
Review descriptions for our medical therapeutic area list to help
assist in your search.
Join our Drug Research Updates group on LinkedIn!
Find out more about the types of drugs included in this listing.
2006
Cardiology/Vascular Diseases
Ranexa (ranolazine); CV Therapeutics;
For the treatment of chronic angina in patients failing first-line therapy, Approved January 2006
Dermatology
Desonate (desonide); Dow Pharm;
For the treatment of atopic dermatitis, Approved October 2006
Verdeso (desonide); Connetics Corporation;
For the treatment of atopic dermatitis, Approved September 2006
Endocrinology
Elestrin (estradiol gel); BioSante;
For the treatment of vasomotor symptoms associated with menopause, Approved December 2006
Januvia (sitagliptin phosphate); Merck;
For the treatment of type II diabetes, Approved October 2006
Family Medicine
Desonate (desonide); Dow Pharm;
For the treatment of atopic dermatitis, Approved October 2006
Elestrin (estradiol gel); BioSante;
For the treatment of vasomotor symptoms associated with menopause, Approved December 2006
Eraxis (anidulafungin); Pfizer;
For the treatment of Candida fungal infections, Approved February 2006
Januvia (sitagliptin phosphate); Merck;
For the treatment of type II diabetes, Approved October 2006
Noxafil (posaconazole); Schering-Plough;
For the treatment of fungal infections, Approved in September 2006
Prezista (darunavir); Tibotec;
For the treatment of treatment-resistant HIV infections, Approved June 2006
Ranexa (ranolazine); CV Therapeutics;
For the treatment of chronic angina in patients failing first-line therapy, Approved January 2006
Vectibix (panitumumab); Amgen;
For the treatment of colorectal cancer, Approved September 2006
Verdeso (desonide); Connetics Corporation;
For the treatment of atopic dermatitis, Approved September 2006
Vivitrol (naltrexone for extended-release injectable suspension); Alkermes;
For the treatment of alcohol dependence, Approved April 2006
Gastroenterology
Amitiza (lubiprostone); Sucampo/Takeda;
For the treatment of chronic idiopathic constipation, Approved January 2006
Hematology
Dacogen (decitabine); MGI Pharma;
For the treatment of both treatment-naïve and -experienced Myelodysplastic Syndromes, Approved May 2006
Hepatology (Liver, Pancreatic, Gall Bladder)
Tyzeka (telbivudine); Idenix Pharma;
For the treatment of hepatitis B virus, Approved October 2006
Immunology
Eraxis (anidulafungin); Pfizer;
For the treatment of Candida fungal infections, Approved February 2006
Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine); Merck;
For the prevention of cervical cancer associated with human papillomavirus, Approved June 2006
Noxafil (posaconazole); Schering-Plough;
For the treatment of fungal infections, Approved in September 2006
Prezista (darunavir); Tibotec;
For the treatment of treatment-resistant HIV infections, Approved June 2006
Rotateq (rotavirus vaccine, live oral pentavalent); Merck;
For the prevention of gastroenteritis associated with rotavirus infections in infants, Approved February 2006
Tyzeka (telbivudine); Idenix Pharma;
For the treatment of hepatitis B virus, Approved October 2006
Veregen (kunecatechins); Medigene;
For the treatment of external genital and perianal warts, Approved October 2006
Infections and Infectious Diseases
Eraxis (anidulafungin); Pfizer;
For the treatment of Candida fungal infections, Approved February 2006
Noxafil (posaconazole); Schering-Plough;
For the treatment of fungal infections, Approved in September 2006
Prezista (darunavir); Tibotec;
For the treatment of treatment-resistant HIV infections, Approved June 2006
Tyzeka (telbivudine); Idenix Pharma;
For the treatment of hepatitis B virus, Approved October 2006
Veregen (kunecatechins); Medigene;
For the treatment of external genital and perianal warts, Approved October 2006
Neurology
Invega (paliperidone); Janssen Pharmaceuticals;
For the treatment of schizophrenia, Approved December 2006
Vivitrol (naltrexone for extended-release injectable suspension); Alkermes;
For the treatment of alcohol dependence, Approved April 2006
Obstetrics/Gynecology (Women’s Health)
Elestrin (estradiol gel); BioSante;
For the treatment of vasomotor symptoms associated with menopause, Approved December 2006
Oncology
Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine); Merck;
For the prevention of cervical cancer associated with human papillomavirus, Approved June 2006
Sprycel (dasatinib); Bristol-Myers Squibb;
For the treatment of imatinib-resistant chronic myeloid leukemia, Approved June 2006
Sutent (sunitinib); Pfizer;
For the treatment of kidney cancer and gastrointestinal stromal tumors, Approved January 2006
Vectibix (panitumumab); Amgen;
For the treatment of colorectal cancer, Approved September 2006
Ophthalmology
Lucentis (ranibizumab); Genentech;
For the treatment of neovascular (wet) age related macular degeneration, Approved June 2006
Pediatrics/Neonatology
Desonate (desonide); Dow Pharm;
For the treatment of atopic dermatitis, Approved October 2006
Elaprase (idursulfase); Shire Pharmaceuticals;
For the treatmenr of mucopolysaccharidosis II (Hunter Syndrome), Approved July 2006
Myozyme (alglucosidase alfa); Genzyme;
For the treatment of Pompe disease (glycogen storage disease type II), Approved April 2006
Podiatry
Veregen (kunecatechins); Medigene;
For the treatment of external genital and perianal warts, Approved October 2006
Psychiatry/Psychology
Chantix (varenicline); Pfizer;
For the treatment of nicotine addiction, Approved May 2006
Invega (paliperidone); Janssen Pharmaceuticals;
For the treatment of schizophrenia, Approved December 2006
Vivitrol (naltrexone for extended-release injectable suspension); Alkermes;
For the treatment of alcohol dependence, Approved April 2006
Pulmonary/Respiratory Diseases
Brovana (arformoterol tartrate); Sepracor;
For the treatment of Chronic Obstructive Pulmonary Disease, Approved in October 2006
Rheumatology
Elaprase (idursulfase); Shire Pharmaceuticals;
For the treatmenr of mucopolysaccharidosis II (Hunter Syndrome), Approved July 2006
